ONO-1110
Small molecule
Evidence outlook
Fibromyalgia: topline reported 2026-10-29
The sponsor reported topline results on 2026-10-29 (Ono reports Phase 2 results of ONO-1110: the PHN, fibromyalgia and HIC studies missed their primary endpoints). The announcement is listed under Regulatory events.
Development in Major Depressive Disorder stopped (2026-10-29) after a negative readout. Development continues in another indication. Source
Development in Social Anxiety Disorder stopped (2026-10-29) after a negative readout. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06752590 NCT06752590 · Fibromyalgia Registry: NCT06752590 | 2 | Change in weekly mean of average pain score from baseline to Week 8 of the treatment period (Up to 16 weeks); Adverse events (Up to 16 weeks) 2026-05-30 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Fibromyalgia: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ONO-1110: this drug | Phase 2 | Small molecule | Endocannabinoid synthesis | not yet graded | No reviewed efficacy summary in this indication | |
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | Partial signal | NCT04172831: Change in weekly average daily pain (NRS) from baseline to week 14: TNX-102 SL 5.6 mg -1.9 vs placebo -1.5; LS mean difference -0.4 (95% CI -0.7 to -0.1), p=0.010 (n=248 and 255) (CT.gov posted results). NCT04508621: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. (14 weeks): TNX-102 SL Tablet, 5.6 mg -1.6 score on a scale (95% CI -1.8 to -1.3) | Placebo SL Tablet -1.3 score on a scale (95% CI -1.5 to -1.1) missed | |
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | not yet graded | No reviewed efficacy summary in this indication | |
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Esreboxetine | Phase 3 | Small molecule | norepinephrine transporter | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent